Taikoh , a good example of the possible profitability is Lilleys Alimta(permatrexed). It was approved in Feb for mesothelioma and has just been approved for NSCLC . It showed small improvement in mesothelioma patients and and in the trials against NSCLC showed an improved survival of 8.3 months , versus the standard treatment, docitaxel, of 7.9 months . The alimta has milder side effects than docitaxel , so the FDA approved it . Lilley expects to be making $US628million in sales P.A. by 2008 . It is possible to make huge profits with an improvement , without having a full cure . And what do you think an outfit like Lilley would pay for the drug that will possibly push Alimta out of the market .
h**p://www.enquirer.com/editions/2004/08/20/biz_bizdigest20.html
SBP
solbec pharmaceuticals limited
